WallStreetZenWallStreetZen

NASDAQ: RNA
Atrium Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Atrium Therapeutics revenue was N/A for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2026) ending on Mar 31, 2026 was $19.6M, up 2,185.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RNA annual revenue was $18.6M, with 70.9% growth year-over-year.

RNA revenue history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

Be the first to know when RNA announces revenue.

RNA Revenue History By Year

RNA Yearly RevenueRNA RevenueRNA ChangeRNA Revenue Growth
2025-12-31$18.62M$7.72M+70.85%
2024-12-31$10.90M$1.13M+11.60%
2023-12-31$9.76MN/AN/A

1 of 1

Atrium Therapeutics Revenue FAQ

What was RNA's revenue last quarter?

On Invalid Date, Atrium Therapeutics (NASDAQ: RNA) reported Q1 2026 revenue of $19.64 million up 1,148.25% year over year. In the same quarter last year, Atrium Therapeutics's revenue was $1.57 million.

What was Atrium Therapeutics's revenue in 2025?

Atrium Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $18.62 million, a 70.85% increase year over year.

How much does Atrium Therapeutics make in a day?

Based on Atrium Therapeutics annual revenue for the past two years, RNA makes an average of $40,431.51 per day.

What was Atrium Therapeutics's annual revenue growth in the past year?

As of Q2 2026, Atrium Therapeutics's revenue has grown null year over year. Atrium Therapeutics's revenue in the past year totaled N/A.

How much does Atrium Therapeutics make in a year?

Atrium Therapeutics's revenue by year for the past two years is:
  • Atrium Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $18.62 million, a 70.85% increase year over year.
  • Atrium Therapeutics's annual revenue for Dec 31, 2024 was $10.90 million, a 11.6% increase from 2023.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.